Abstract
Staphylococcus aureus is responsible for many nosocomial and community-acquired infections. Its evolving resistance to traditional antimicrobial chemotherapy and emerging prevalence outside of the healthcare environment are serious concerns. This review of the changing epidemiology of methicillin-resistant S. aureus, the emergence of vancomycin (glycopeptide)-resistant isolates, and the mechanisms of resistance to beta-lactams and glycopeptides provides an update for clinicians regarding effective strategies for treatment.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
-
Review
MeSH terms
-
Anti-Bacterial Agents / therapeutic use*
-
Community-Acquired Infections / drug therapy
-
Community-Acquired Infections / epidemiology
-
Community-Acquired Infections / prevention & control
-
Cross Infection / drug therapy
-
Cross Infection / epidemiology
-
Cross Infection / prevention & control
-
Humans
-
Methicillin Resistance
-
Staphylococcal Infections / drug therapy*
-
Staphylococcal Infections / epidemiology
-
Staphylococcal Infections / prevention & control
-
Staphylococcus aureus / drug effects*
-
Vancomycin Resistance